VotedBy VotedBy ⌕
Election Day · Tue, Nov 3See how your members of Congress voted →

H.R. 733 · 112th Congress

Pancreatic Cancer Research and Education Act

Key: what the circles and colors mean

Each circle is a bill. The ring fills as it moves through Congress:

IntroducedPassed one chamberPassed both chambersBecame law (gold)Resolution agreed to (full, dark)Failed or vetoed (gray)

Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.

Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.

Passed the House without a recorded vote, then expired. It passed by voice vote or unanimous consent, which don't record how each member voted, but didn't become law before the 112th Congress ended.

AED EshooSponsor
294 cosponsors · 181 D, 113 R
LLR Lance DRR Reichert RHD Holt JMD Moran MRD Ross ECD Cummings GND Napolitano JGR Gerlach JSD Sarbanes TLR Latham JYD Yarmuth GAD Ackerman SBD Berkley JCD Cooper MCD Capuano JCD Costa MHD Hinchey SID Israel ZLD Lofgren BLD Lee RND Neal NDD Dicks JLD Lewis CMD Maloney FPD Pallone CRD Rangel JSD Schakowsky ASD Schiff MTR Turner MFR Fitzpatrick NLD Lowey GMD Moore JMD McNerney END Norton DDD DeGette SDD Davis SLD Lynch JMD McGovern DMR McKinley RCD Carnahan DLD Loebsack RNR Nugent BPD Pascrell CVD Van Hollen JDD Donnelly PTR Tiberi NTD Tsongas SCR Capito FWR Wolf TBD Baldwin EJD Johnson TRD Ryan BBD Braley EED Engel LRD Roybal-Allard RDD DeLauro CFD Fattah JDR Denham DPD Payne YCD Clarke TMR Murphy EPD Pastor MBR Burgess MHD Honda CMD Murphy RBD Brady PSD Stark TDD Deutch CGD Gonzalez EPD Perlmutter PPD Pierluisi JAD Altmire TBD Bishop JBD Barrow LBR Barletta BCD Chandler KCD Castor JCD Courtney GCD Connolly DDD Davis MDD Doyle SFD Farr BFD Frank MFD Fudge GHR Harper MKD Kaptur LKD Kissell PMR McHenry TMR Marino DPD Price TPR Platts CPD Pingree SRD Rothman LRD Richardson BSD Scott PSR Sessions ASD Smith ASD Sires BTD Thompson LTR Terry MTD Thompson DWD Wu JCR Carter KED Ellison BFD Filner BGR Goodlatte NRD Rahall SSR Stivers KCR Calvert JCR Culberson EGR Gallegly SJD Jackson Lee HJD Johnson JMD McDermott MMD Michaud CBD Brown VBR Buchanan ACR Crenshaw JOD Olver BRD Rush DRR Ross DYR Young WAR Akin BGR Guthrie SPR Palazzo GPD Peters HBD Berman ECD Cleaver DCD Cicilline WKD Keating BPR Posey DKD Kucinich JND Nadler BSR Shuster JSR Schmidt JWR Wilson FLR LoBiondo EMD Markey LWD Woolsey MQD Quigley LBD Boswell AGD Green JRR Runyan HCD Clarke EPR Paulsen JJD Jackson GMD Meeks JSD Speier LCD Capps BLR Luetkemeyer PWD Welch CPD Peterson JTD Tierney MBD Bordallo GGD Green JGD Garamendi RHR Hanna BJR Johnson DKD Kildee JLD Langevin TWD Walz CBR Bass PMR Meehan PKR King CSR Smith RBR Bartlett WJR Jones BBR Bilbray RFR Frelinghuysen ETD Towns WCD Clay WOD Owens LGD Gutiérrez SBD Bishop RKD Kind LDD Doggett CDR Dent JID Inslee CMD McCarthy TMR McCotter BMD Miller CRD Ruppersberger SBR Bachus TGR Griffin JHD Hahn SRD Reyes LSD Slaughter CBR Boustany SCD Cohen BCR Cassidy DMD Matsui JHD Himes THD Holden HGR Griffith JSD Serrano DCD Cardoza RHR Hurt TRR Reed DLD Lipinski LSD Sánchez GBR Bilirakis AHD Hastings JCD Conyers RCR Crawford RGD Grijalva MHD Hirono TPR Poe XBD Becerra JBD Baca KBD Bass JCD Chu GMD Miller BMD McCollum LSD Sanchez ASD Schwartz NVD Velázquez MWD Waters DCD Christensen RHR Hall PGR Gingrey JCD Costello JBR Biggert PBR Broun NHR Hayworth JLD Larson CMR McMorris Rodgers GKD Butterfield CMR Miller KMR Marchant KNR Noem ASR Scott DWD Wasserman Schultz KGR Granger MAR Amodei BLR Long MGR Grimm RLD Larsen SWR Womack AHR Harris JMD Matheson MHD Heinrich MBR Blackburn SBD Bonamici SLR LaTourette HWD Waxman JCD Carney JBR Bonner MKR Kelly ANR Nunnelee BSD Sherman DSD Scott RAD Andrews AMR Marie Buerkle IRR Ros-Lehtinen MBR Brooks JCR Chaffetz EWR Whitfield EBD Blumenauer MBR Bono Mack RBR Berg MDR Diaz-Balart SGR Graves SLD Levin RLR Latta JPD Polis CYR Young MCD Critz FGR Guinta RRR Ribble JDD Dingell DRR Rivera PTD Tonko KYR Yoder CRD Richmond KSD Schrader SDR Duffy MMD McIntyre MSR Simpson MBR Bachmann KMR McCarthy RBR Bishop CHD Hanabusa BLD Luján JRR Renacci BSR Schilling CSR Stearns ACD Carson TFR Franks JMR Mica GWR Walden RBD Barber MRR Roby PDD DeFazio PRR Roskam

2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.

  1. House Introduced Feb 16, 2011
  2. House Passed Sep 19, 2012

Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings,…

What it does: CRS summary · Passed House amended · Sep 19, 2012

Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research; (2) identification of research questions that have not been adequately addressed; and (3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions. Requires the Director to develop the framework within 18 months and review and update it every 5 years.

Requires the Director to identify within 6 months 2 or more recalcitrant cancers that have a 5-year relative survival rate of less than 20%, and are estimated to cause the death of at least 30,000 individuals in the United States per year. Authorizes the Director to identify additional such cancers and to consider additional metrics of progress (such as incidence and mortality rates) against such cancer.

Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act.

Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.

Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov

About this bill and sources

Official title: Recalcitrant Cancer Research Act of 2012

Latest action (Sep 20, 2012): Received in the Senate.

Policy area: Health · Origin: House · Introduced: Feb 16, 2011

Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)

  1. House Introduced Feb 16, 2011
  2. House Passed Sep 19, 2012

No recorded floor vote found.